Company CureVac N.V.

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for CureVac N.V.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
2.33 ^USD	+0.87%		-4.51%	-44.66%

26/04	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT
25/04	Leerink Partners Downgrades CureVac to Market Perform From Outperform, Sets Price Target at $4	MT

CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Number of employees: 977

USD in Million	2022	Weight	2023	Weight	Delta
Transformative Medicines Based on Messenger Ribonucleic Acid 100.0 %	71	100.0 %	58	100.0 %	-17.98%

USD in Million	2022	Weight	2023	Weight	Delta
Belgium 87.7 %	65	92.4 %	51	87.7 %	-22.14%
Switzerland 10.1 %	4	5.0 %	6	10.1 %	+65.60%
Netherlands 2.2 %	2	2.7 %	1	2.2 %	-31.10%
Others 0.0 %	-	-	0	0.0 %	-

Managers	Title	Age	Since
Alexander Zehnder CEO	Chief Executive Officer	54	28/23/28
Pierre Kemula DFI	Director of Finance/CFO	50	01/16/01
Malte Greune COO	Chief Operating Officer	59	01/21/01
Sarah Fakih IRC	Investor Relations Contact	-	-
Myriam Mendila PRN	Corporate Officer/Principal	58	01/23/01
Patrick Baumhof PRN	Corporate Officer/Principal	-	-
Antony Blanc PRN	Corporate Officer/Principal	57	04/20/04
Ulrike Gnad-Vogt PRN	Corporate Officer/Principal	-	01/11/01

Members of the board	Title	Age	Since
Craig Tooman BRD	Director/Board Member	58	01/19/01
Michael Brosnan BRD	Director/Board Member	69	19/23/19
Klaus Schollmeier BRD	Director/Board Member	67	22/22/22
Baron Jean Stéphenne CHM	Chairman	73	01/15/01
Mathias Hothum BRD	Director/Board Member	58	01/15/01
Debra Stephanie Barker BRD	Director/Board Member	61	22/22/22
Viola Bronsema BRD	Director/Board Member	61	01/20/01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	223,923,708	122,200,574 ( 54.57 %)	0	54.57 %

Name	Equities	%	Valuation
dievini Hopp BioTech holding GmbH & Co. KG 31.35 %	70,181,760	31.35 %	213 M $
Government of Germany 13.34 %	29,871,441	13.34 %	91 M $
GSK PLC 7.411 %	16,591,937	7.411 %	50 M $
Dietmar Hopp 4.598 %	10,294,503	4.598 %	31 M $
Zweite DH Verwaltungs GmbH 1.521 %	3,404,672	1.521 %	10 M $
RA Capital Management LP 1.226 %	2,744,270	1.226 %	8 M $
Millennium Management LLC 1.219 %	2,728,903	1.219 %	8 M $
T Rowe Price Associates, Inc. (13F Subfiler) 1.038 %	2,324,274	1.038 %	7 M $
Camber Capital Management LP 0.7817 %	1,750,000	0.7817 %	5 M $
BlackRock Advisors LLC 0.7466 %	1,671,504	0.7466 %	5 M $

CureVac NV

Friedrich-Miescher-Strasse 15

72076, Tübingen

+49 7071 9883 0

http://www.curevac.com

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.183 EUR

Average target price

12.89 EUR

Spread / Average Target

+490.70%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CUREVAC N.V.	-44.66%	522M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research